Morgan Stanley & Co. LLC
1585 Broadway
New York, New York 10036
SVB Leerink LLC
255 California Street, 12th Floor
San Francisco, California 94111
February 2, 2021
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Bolt Biotherapeutics, Inc. |
Registration Statement on Form S-1, as amended (File No. 333-252136)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Bolt Biotherapeutics, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 PM, Eastern Time, on February 4, 2021, or as soon thereafter as practicable, or at such other time thereafter as the Company or its outside counsel, Cooley LLP, may request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that we have carried out the following distribution of the Company’s preliminary prospectus dated February 1, 2021:
| (i) | Dates of distribution: February 1, 2021 through the date hereof |
| (ii) | Number of prospective underwriters to which the preliminary prospectus was furnished: 4 |
| (iii) | Number of preliminary prospectuses furnished to investors: approximately 2,600 |
| (iv) | Number of preliminary prospectuses distributed to others, including the Company, the Company’s counsel, independent accountants and underwriters’ counsel: approximately 4 |
The undersigned advise that they have complied and will continue to comply, and each underwriter has advised the undersigned that it has complied and will continue to comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Signature Page Follows]
| Very truly yours, | ||
| MORGAN STANLEY & CO. LLC SVB LEERINK LLC
As representatives of the several underwriters listed in Schedule I to the Underwriting Agreement | ||
| MORGAN STANLEY & CO. LLC | ||
| By: | /s/ Kalli Dircks | |
| Name: Kalli Dircks | ||
| Title: Managing Director | ||
| SVB LEERINK LLC | ||
| By: | /s/ Murphy Gallagher | |
| Name: Murphy Gallagher | ||
| Title: Managing Director | ||
[Signature Page to Underwriters’ Acceleration Request]